The flags with the logos of the Danish drug manufacturer Novo Nordisk, manufacturer of the successful diabetes and the weight loss treatments Ozempic and Wogovy are images, while the company presents the annual report in Novo Nordisk in Bagvaerd, Denmark, on February 525.
Mads Claus Rasmussen | AFP | Getty images
Novo Nordisk’s actions increased almost 7% on Wednesday after saying that sales of their great weight loss were improving in the second half of the year, since the availability of medicines composed of imitation is eliminated.
The Danish pharmaceutical giant reported sales of the first quarter lower than expected of its flagship of obesity and cut its prognosis of sales growth throughout the year since the alternative versions of the medication have far in their market share.
However, CEO Lars Fruerd Jørgensen told CNBC that the end of a drug shortage decision by the Food and Drug Administration (FDA) would allow sales to return to resume later in the year.
“The compounds took a part of our business,” Jørgensen told Charlotte Reed from CNBC.
“Now we expect the compound to be eliminated, so to speak, and we get the growth of the business in the future,” he added.
Novo Nordisk actions increased to 6.7% after comments. The action was last seen at 3.8% at 12:10 pm, London time.
The drug manufacturer reported on Wednesday a better increase than expected in the net gain of the first quarter or 29.03 billion Danish zero ($ 4.4 billion) for the period of three months until the end of March, ahead of Kroner’s prognosis of 27.8 billion Danecast.
Sales of the popular obesity drug of the company increased 83% per year to constant exchange rates to 17.36 billion Danish contributors, a little below 18.51 billion Danish anticipated by analysts in a data survey on Tuesday.
The general revenues in Novo Nordisk, which also produce diabetes and treatments of rare diseases, increased 18% to 78.09 billion Danes versus an expected Danish Koner.
By 2025, the company said that it now sees the growth of sales or from 13% to 21% to constant exchange rates, below 16% to 24% previously predicted in February. The growth of operational profits is forecast between 16% and 24%, compared to 19% to 27% before.
Imitation drugs
Jørgensen attributed the reduced forecast to increase the competition of compounded weight loss drugs in the US at the beginning of the year.
“In the first quarter of 2025, we offered a sales growth of 18% and continue to expand the scope of our innovative GLP-1 treatments,” Jørgensen said in a statement.
“However, we have reduced our full-year perspective due to the lowest LPG-1 penetration of the planned brand, which is affected by the rapid expansion of composition in the United States”
The US composed pharmacies had allowed to make legal copies of Novo drugs and Ozempic diabetes under a Drug Shortage decision by the FDA.
The FDA declared that scarcity in February, giving composition pharmacies until May 22 to stop selling copies of the medicine. As such, Novo said that he hopes that the sales of compound alternatives are soon, and reiterated that he would persecute companies that continue to distribute such imitative medications illegally.
“After the elimination of the US FDA.
Jørgensen also pointed out the launch of a new in -line to consumer and associations with Telesalud Hims & Hers Health, RO and LIFEMD, which said they would reduce Wagovy’s costs and provide a “safe and reliable and reliable” linges for patients.
An advertisement last week of CVS Health, which will expand access to WOGOVY for patients covered by its pharmacy benefits manager, CaMark, will only join that access.
“Now competitive products have excluded, so we have exclusivity with them,” Jørgensen said. “We do not offer for exclusivity. We believe in open access, so it was CVS that made the decision to focus on Wagovy.”
Emily Field, director of the investigation of European pharmaceutical products in Barclays, told the “Squawk” CNBC box that the key indicator for Novo would be if they can generate a prescription volume growth in the US. UU. When the competition of the compounds disappears.
“On summer, it will be put or shut up for Wagovy. Either scripts [prescriptions] Return, or I think people will only assume that Lilly takes this entire market, “he said.
Competition is heated
The results occur in the midst of the fugitive demand of the treatment loss loss of the drug manufacturer, which work imitating a glucagon-shaped peptide 1 similar to a hormone similar to the call to suppress the appetite.
However, the company has struggled to shake the negative feeling after a series of disappointing results of the trials for its next -generation candidate for obesity drug.
Novo Nordisk confirmed Wednesday that he plans to request the regulatory approach of Cagrisema in the first quarter of 2026. Meanwhile, he has requested the regulatory approval of the US. UU. Or an oral version of the glut’s glut of the glut of the treatment treatment for obesity. “
“I am very optimistic with Cagrisema,” Jørgensen said. “From the data we have, Cagrisema is the best product that has been tested or in the market, and we believe that we can obtain those data even better.”
The competition is warming up in the weight of weight drugs, with pharmaceutical companies that include Roche” Astrazeneca and Abbot All new potential candidates currently develop possible.
The rival of the United States of Novo, Eli Lilly, in Thorsday, reported a 45% expectation increase in sales of the first quarter, although the income for its popular Zepbound weight loss drug arose at a lower price than in the lowest drug prices. The US drug manufacturer. UU. It also reduced its profit guide throughout the year due to charges related to a recent cancer treatment agreement, which sends lower actions.
